| Jun 8, 2026 | finance.yahoo.com | Weekly Roundup on the Cannabis Sector & Psychedelic Sector |
| Jun 5, 2026 | finance.yahoo.com | Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar |
| May 29, 2026 | stocktwits.com | Why Did CMND Stock Jump 40% Today? |
| May 29, 2026 | finance.yahoo.com | Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment |
| May 26, 2026 | finance.yahoo.com | Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts |
| May 21, 2026 | finance.yahoo.com | Is Clearmind Medicine (NASDAQ:CMND) In A Good Position To Deliver On Growth Plans? |
| May 19, 2026 | finance.yahoo.com | Clearmind Medicine Announces 1-for-10 Reverse Share Split |
| May 18, 2026 | investorshub.advfn.com | Tirzepatide Combination Study Expands Clearmind’s Obesity Therapy Strategy (CMND) |
| May 18, 2026 | finance.yahoo.com | Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications |
| May 15, 2026 | finance.yahoo.com | Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. |
| May 12, 2026 | finance.yahoo.com | Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder |
| May 11, 2026 | finance.yahoo.com | Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial |
| May 5, 2026 | finance.yahoo.com | Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD |
| Apr 27, 2026 | finance.yahoo.com | Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation |
| Apr 27, 2026 | finance.yahoo.com | Weekly Roundup on the Cannabis Sector & Psychedelic Sector |
| Apr 24, 2026 | finance.yahoo.com | FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain |
| Apr 20, 2026 | finance.yahoo.com | Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental Illness |
| Apr 20, 2026 | finance.yahoo.com | Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial |
| Apr 20, 2026 | finance.yahoo.com | Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care |
| Apr 18, 2026 | finance.yahoo.com | Trump Trade: President to sign order on psychedelic used for PTSD |
| Apr 15, 2026 | finance.yahoo.com | Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial |
| Apr 14, 2026 | finance.yahoo.com | Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder |
| Mar 30, 2026 | finance.yahoo.com | Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder |
| Mar 27, 2026 | finance.yahoo.com | Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders |
| Mar 19, 2026 | finance.yahoo.com | Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder |
| Mar 17, 2026 | finance.yahoo.com | Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies |
| Mar 16, 2026 | finance.yahoo.com | NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy |
| Mar 16, 2026 | finance.yahoo.com | SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy |
| Mar 13, 2026 | finance.yahoo.com | Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy |
| Mar 12, 2026 | finance.yahoo.com | SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease |
| Mar 11, 2026 | finance.yahoo.com | NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease |
| Mar 11, 2026 | finance.yahoo.com | Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results |
| Mar 10, 2026 | finance.yahoo.com | Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease |
| Mar 6, 2026 | finance.yahoo.com | Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results |
| Mar 4, 2026 | finance.yahoo.com | Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval |
| Feb 19, 2026 | www.prnewswire.com | /PRNewswire/ -- As the multi-billion-dollar obesity treatment market continues to search for new therapeutic approaches beyond GLP-1–based treatments,... |
| Feb 19, 2026 | finance.yahoo.com | Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss? |
| Feb 16, 2026 | finance.yahoo.com | Weekly Roundup on the Cannabis Sector & Psychedelic Sector |
| Feb 9, 2026 | finance.yahoo.com | Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial |
| Feb 8, 2026 | finance.yahoo.com | Weekly Roundup on the Cannabis Sector & Psychedelic Sector |
| Feb 6, 2026 | finance.yahoo.com | Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation |
| Feb 6, 2026 | finance.yahoo.com | Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI |
| Feb 3, 2026 | finance.yahoo.com | Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments |
| Jan 20, 2026 | finance.yahoo.com | Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 |
| Jan 14, 2026 | finance.yahoo.com | Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 |
| Dec 31, 2025 | finance.yahoo.com | Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement |
| Dec 24, 2025 | finance.yahoo.com | Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth |
| Dec 16, 2025 | finance.yahoo.com | Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 |
| Dec 15, 2025 | finance.yahoo.com | Weekly Roundup on the Cannabis Sector & Psychedelic Sector |
| Dec 12, 2025 | finance.yahoo.com | Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement |
| Dec 12, 2025 | finance.yahoo.com | Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment |
| Dec 10, 2025 | finance.yahoo.com | Clearmind Medicine Announces 1-for-40 Reverse Share Split |
| Dec 5, 2025 | finance.yahoo.com | Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification |
| Dec 2, 2025 | finance.yahoo.com | BC-Most Active Stocks |
| Dec 2, 2025 | finance.yahoo.com | Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder |
| Dec 1, 2025 | finance.yahoo.com | Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial |
| Nov 25, 2025 | finance.yahoo.com | Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial |
| Nov 24, 2025 | finance.yahoo.com | Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review |
| Nov 23, 2025 | finance.yahoo.com | Weekly Roundup on the Cannabis Sector & Psychedelic Sector |
| Nov 20, 2025 | finance.yahoo.com | SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression |
| Nov 20, 2025 | finance.yahoo.com | Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site |
| Nov 19, 2025 | finance.yahoo.com | Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression |
| Nov 18, 2025 | finance.yahoo.com | Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder |
| Nov 18, 2025 | finance.yahoo.com | BC-Most Active Stocks |
| Nov 17, 2025 | finance.yahoo.com | Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression |
| Nov 13, 2025 | finance.yahoo.com | BC-Most Active Stocks |
| Nov 13, 2025 | finance.yahoo.com | Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center |
| Nov 12, 2025 | finance.yahoo.com | Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment |
| Nov 10, 2025 | finance.yahoo.com | Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder |
| Nov 6, 2025 | finance.yahoo.com | Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency |
| Nov 5, 2025 | finance.yahoo.com | Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing |
| Nov 2, 2025 | finance.yahoo.com | Weekly Roundup on the Cannabis Sector & Psychedelic Sector |
| Oct 31, 2025 | finance.yahoo.com | Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy |
| Oct 30, 2025 | finance.yahoo.com | Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder |
| Oct 28, 2025 | finance.yahoo.com | Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar |
| Oct 27, 2025 | finance.yahoo.com | Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement |
| Oct 21, 2025 | finance.yahoo.com | Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder |
| Sep 25, 2025 | finance.yahoo.com | Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies |
| Sep 19, 2025 | finance.yahoo.com | Clearmind Medicine Signs Deal to Raise Up to $10 Million Through Convertible Notes |
| Sep 19, 2025 | finance.yahoo.com | Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities |
| Aug 7, 2025 | finance.yahoo.com | Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar |
| Aug 7, 2025 | finance.yahoo.com | SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar |
| Aug 5, 2025 | finance.yahoo.com | Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center |
| Jul 30, 2025 | finance.yahoo.com | SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease |
| Jul 30, 2025 | finance.yahoo.com | Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease |
| Jul 23, 2025 | finance.yahoo.com | Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder |
| Jul 20, 2025 | finance.yahoo.com | Weekly Roundup on the Cannabis Sector & Psychedelic Sector |
| Jul 15, 2025 | finance.yahoo.com | Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled |
| Jul 9, 2025 | finance.yahoo.com | Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck |
| Jul 3, 2025 | finance.yahoo.com | Sector Update: Health Care Stocks Mixed Thursday Afternoon |
| Jul 3, 2025 | finance.yahoo.com | Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center |
| Jun 30, 2025 | finance.yahoo.com | Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder |
| Jun 27, 2025 | finance.yahoo.com | Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial |
| Jun 27, 2025 | finance.yahoo.com | Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market |
| Jun 25, 2025 | finance.yahoo.com | Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment |
| Jun 24, 2025 | finance.yahoo.com | Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics |
| Jun 23, 2025 | finance.yahoo.com | Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder |
| Jun 19, 2025 | finance.yahoo.com | Trump Trade: President said to weigh possible U.S. strike against Iran |
| Jun 19, 2025 | finance.yahoo.com | Psychedelic advocates hopeful Trump administration will support space, STAT says |
| Jun 12, 2025 | finance.yahoo.com | Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics |